GraniteShares 2x Long COIN Daily ETF vs Eli Lilly And Co — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $4.09, while Eli Lilly And Co trades at $1,215.1 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while GraniteShares 2x Long COIN Daily ETF pays none. Which is the better fit depends on your goals.
| CONL | LLY | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $48.70 | $1.24K |
52-Week Low | $3.93 | $639.43 |
Market Cap | — | $1.10T |
Enterprise Value | — | $1.14T |
Dividend Yield | — | 0.56% |
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.38, up 11.45% in the past 24 hours but remains significantly below year-to-date levels with a 67% decline. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF tracks Coinbase stock with 2x daily leverage, exposing investors to amplified volatility from cryptocurrency market movements.
The outlook remains challenging due to the volatility decay inherent in daily-reset leveraged products. While recent cryptocurrency strength provides potential upside, the structural design of CONL creates significant long-term erosion risk. Investors should understand the product's mechanics before considering positions in this high-risk instrument.
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
Trailing returns across standard periods
Latest headlines on both assets
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →